AARP supports the development of a Minnesota state Drug Affordability Review Board and believes that federal, state, and local governments should ensure that prescription drug launch prices and subsequent pricing decisions are reasonable, justified, and support improved consumer access and affordability
Advocating for what is important to our members and giving you a voice at the state and federal level is a priority for AARP Minnesota. Your voice matters. Legislators appreciate hearing from constituents, so they know how bills will affect you and your family. Knowing more about AARP Minnesota's legislative priorities is helpful as you prepare to make a call, send an email, or prepare to testify before a committee.
When the Virginia General Assembly returns to work on Wednesday, AARP volunteers will ask lawmakers for legislation to help workers save for retirement, require prescription drug price transparency, and overhaul oversight of the state’s long-term care facilities.
The Rally to Stop Rx Greed has been postponed. While convening events such as this is a core part of our mission, we have changed our approach in light of the coronavirus (COVID-19) outbreak. We will update this page if the event is rescheduled.
AARP Kentucky Calls for Passage of House Bill 12. No one should be forced to choose between putting food on the table or buying a lifesaving medication. Call the Legislative Message line 1-800-372-7171 and tell your lawmakers in the Kentucky House to vote YES on House Bill 12.
24% of NYers 50+ Skipped Prescription Meds in Past Two Years – Most Because of Cost: AARP Voter Survey
AARP Urges NYS Lawmakers to Support Proposals to Increase Accessibility of Affordable Drugs, Crack Down on Price Gouging, Expose Costly Deals
A crowd of supporters of AARP's Rx Greed campaign turned out at a rally on the Detroit River to support measures that would cut prescription drug prices, including an importation bill currently in the Michigan Legislature.
It is getting expensive out there! Retail prices for 267 brand-name drugs commonly used by older adults surged by an average of 5.8% in 2018, more than twice the general inflation rate of 2.4%, according to new AARP Public Policy Institute data.
American taxpayers contribute billions towards the development of new drugs. But Medicare isn’t able to negotiate lower drug prices, leaving taxpayers to pay the price.
Search AARP States
Sign Up & Stay Connected